Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis

Seguin, Amélie; Galicier, Lionel; Boutboul, David; Lemiale, Virginie; Azoulay, Élie

doi:10.1016/j.chest.2015.11.004

Cited by 135 publications

(125 citation statements)

References 20 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…However, after HPS-specific and etiotropic treatments, patients with respiratory function improvement were only 67/118 (56.7%). [23] The results from an autopsy also verified a hemophagocytic phenomenon in the lungs of patients. [25] In this study, the risk of death for patients with pulmonary involvement obviously increased, which was consistent with previous studies.…”

Section: Discussionmentioning

confidence: 88%

“…A study on children with HPS revealed pleural effusion in 60% patients by imaging. [22] Seguin et al [23] conducted pulmonary high-resolution computed tomography examinations on 68 patients who were diagnosed with HPS, and 38 of them (56%) had pleural effusion. Matthias et al conducted abdominal ultrasound examinations on 9 children who were diagnosed with HPS and observed peritoneal effusion in 6 patients and pleural effusion in 2 patients, [24] indicating that the incidence of serous effusion was high in HPS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical features and prognostic factors of adult secondary hemophagocytic syndrome

Guo

Bai²,

Gu³

2017

Medicine

View full text Add to dashboard Cite

This study aimed to investigate the relationship between clinical features and prognosis of adult secondary hemophagocytic syndrome (HPS).A retrospective analysis was conducted on the pathogenesis, clinical manifestations, laboratory examinations, treatment options, and prognosis of 47 patients with adult secondary HPS diagnosed from January 2013 to December 2015.The average age at disease onset was (46.26 ± 18.98) years with a male:female ratio of 1:1.14. Thirteen patients died, with the highest mortality rate in patients with HPS underlying blood system malignancy (33.33%, 2/6). The mortality rate in patients with HPS underlying autoimmune disorders was the lowest (18.75%, 3/16). The Kaplan–Meier analysis indicated that signs of hemorrhage, pulmonary and nervous system involvement, serous effusion, and decrease in the blood platelet count were associated with death. The Cox regression analysis revealed that signs of hemorrhage, pulmonary involvement, serous effusion, and nervous system involvement were independent risk factors of patient death.Adult secondary HPS has multiple etiologies and diversified clinical features. The risk of death increases in patients with signs of hemorrhage, serous effusion, pulmonary involvement, and nervous system involvement.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors of adult secondary hemophagocytic syndrome

Guo

Bai²,

Gu³

2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Epidemiologic studies in Japan report the incidence rate at 1 per 800,000 in adults with a median age of 50 years and a male predominance . Published studies note a median survival time of 1.8–2.2 months, and an overall mortality of 42.2% .…”

Section: Discussionmentioning

confidence: 99%

“…Epidemiologic studies in Japan report the incidence rate at 1 per 800,000 in adults with a median age of 50 years and a male predominance [1,2]. Published studies note a median survival time of 1.8-2.2 months, and an overall mortality of 42.2% [3]. Presentation can be diverse, and the primary etiology is unable to be identified in as many as 18% of cases [4].…”

Section: Discussionmentioning

confidence: 99%

Hemophagocytosis lymphocytosis presenting as pulmonary‐renal syndrome: a case report and literature review

Wong

Rao

Nemunaitis

et al. 2017

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Progression to ARDS causes Cytokines Release Syndrome (CRS), that is, the upregulation of pro-inflammatory cytokines and chemokines, and this pattern, is very similar to that of secondary haemophagocytic lymphohistiocytosis (sHLH). Approximately around 50% patients' sHLH causes unrelenting fever, cytopenias and hyperferritinaemia, and pulmonary involvement [42,43]. In the majority of severe COVID-19 infections, a sHLH-like cytokine profile has been reported.…”

Section: Pathophysiology and Related Factsmentioning

confidence: 99%

On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges

et al. 2020

View full text Add to dashboard Cite

Global health is facing the most dangerous situation regarding the novel severe acute respiratory syndrome called coronavirus 2 (SARS-CoV-2), which is widely known as the abbreviated COVID-19 pandemic. This is due to the highly infectious nature of the disease and its possibility to cause pneumonia induced death in approximately 6.89% of infected individuals (data until 27 April 2020). The pathogen causing COVID-19 is called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is believed to be originated from the Wuhan Province in China. Unfortunately, an effective and approved vaccine for SARS-CoV-2 virus is still not available, making the situation more dangerous and currently available medical care futile. This unmet medical need thus requires significant and very urgent research attention to develop an effective vaccine to address the SARS-CoV-2 virus. In this review, the state-of-the-art drug design strategies against the virus are critically summarized including exploitations of novel drugs and potentials of repurposed drugs. The applications of nanochemistry and general nanotechnology was also discussed to give the status of nanodiagnostic systems for COVID-19.

show abstract

Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis

Cited by 135 publications

References 20 publications

Clinical features and prognostic factors of adult secondary hemophagocytic syndrome

Clinical features and prognostic factors of adult secondary hemophagocytic syndrome

Hemophagocytosis lymphocytosis presenting as pulmonary‐renal syndrome: a case report and literature review

On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges

Contact Info

Product

Resources

About